ATS 2019: Video 1 met Marlies Wijsenbeek, Erasmus MC, Rotterdam
May 2019
SSc
ILD
ATS
Marlies Wijsenbeek
nintedanib
SENSCIS Trial
A7360: Nintedanib Reduces Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Results of the SENSCIS Trial.
Longarts Marlies Wijsenbeek over de resultaten van de SENSCIS Trial:
Wilt u meer lezen? Log dan in.